Dr Carlos N Velez
Carlos N Velez, PhD, MBA, is a pharmaceutical and biotechnology strategic advisor, with 25 years’ experience in consulting, venture capital, corporate strategy and entrepreneurship. Carlos specialises in helping pharmaceutical and biotechnology companies develop their in- and out-licensing strategies, with additional expertise and experience in portfolio assessment and prioritisation, drug candidate valuation, valuation and related services. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes. He holds a PhD in pharmacy from the University of North Carolina at Chapel Hill, and an MBA from the Rochester Institute of Technology.
ArticleThe map and compass: integrating BD&L early to de-risk drug discovery
In drug discovery, great science alone is not enough because commercial viability ultimately decides which programmes survive and attract partners. This Q&A explores how integrating Business Development and Licensing (BD&L) from the earliest stages can guide R&D strategy, sharpen decisions and de-risk the path to market.
ArticleFrom siloed data to breakthroughs: multimodal AI in drug discovery
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
ArticleEarly evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
ArticleNavigating the AI revolution: a roadmap for pharma's future
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
ArticleUsing clinical genomics and AI in drug development to elevate success
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.